Comparative Cistromics Reveals Genomic Cross-talk between FOXA1 and ERα in Tamoxifen-Associated Endometrial Carcinomas.

Tamoxifen, a small-molecule antagonist of the transcription factor estrogen receptor alpha (ERα) used to treat breast cancer, increases risks of endometrial cancer. However, no parallels of ERα transcriptional action in breast and endometrial tumors have been found that might explain this effect. In this study, we addressed this issue with a genome-wide assessment of ERα-chromatin interactions in surgical specimens obtained from patients with tamoxifen-associated endometrial cancer. ERα was found at active enhancers in endometrial cancer cells as marked by the presence of RNA polymerase II and the histone marker H3K27Ac. These ERα binding sites were highly conserved between breast and endometrial cancer and enriched in binding motifs for the transcription factor FOXA1, which displayed substantial overlap with ERα binding sites proximal to genes involved in classical ERα target genes. Multifactorial ChIP-seq data integration from the endometrial cancer cell line Ishikawa illustrated a functional genomic network involving ERα and FOXA1 together with the enhancer-enriched transcriptional regulators p300, FOXM1, TEAD4, FNFIC, CEBP8, and TCF12. Immunohistochemical analysis of 230 primary endometrial tumor specimens showed that lack of FOXA1 and ERα expression was associated with a longer interval between breast cancer and the emergence of endometrial cancer, exclusively in tamoxifen-treated patients. Our results define conserved sites for a genomic interplay between FOXA1 and ERα in breast cancer and tamoxifen-associated endometrial cancer. In addition, FOXA1 and ERα are associated with the interval time between breast cancer and endometrial cancer only in tamoxifen-treated breast cancer patients. Cancer Res; 76(13); 3773-84. ©2016 AACR.

[1]  K. Kalland,et al.  Switch in FOXA1 Status Associates with Endometrial Cancer Progression , 2014, PloS one.

[2]  P. Goodfellow,et al.  Hypermethylation of miR-203 in endometrial carcinomas. , 2014, Gynecologic oncology.

[3]  X. Wan,et al.  Forkhead-box A1 suppresses the progression of endometrial cancer via crosstalk with estrogen receptor α. , 2014, Oncology reports.

[4]  X. Wan,et al.  FOXA1 promotes tumor cell proliferation through AR involving the Notch pathway in endometrial cancer , 2014, BMC Cancer.

[5]  J. Foekens,et al.  Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. , 2013, Cancer research.

[6]  Timothy E. Reddy,et al.  Distinct properties of cell-type-specific and shared transcription factor binding sites. , 2013, Molecular cell.

[7]  R. Day,et al.  Gene Expression Analysis of Early Stage Endometrial Cancers Reveals Unique Transcripts Associated with Grade and Histology but Not Depth of Invasion , 2013, Front. Oncol..

[8]  H. Ng,et al.  Uniform, optimal signal processing of mapped deep-sequencing data , 2013, Nature Biotechnology.

[9]  Richard M Myers,et al.  Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner , 2012, Genome research.

[10]  W. E. Hoogendoorn,et al.  Endometrial cancer survival after breast cancer in relation to tamoxifen treatment: Pooled results from three countries , 2012, Breast Cancer Research.

[11]  K. Horie-Inoue,et al.  Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells , 2012, Cancer science.

[12]  I. Ellis,et al.  Differential oestrogen receptor binding is associated with clinical outcome in breast cancer , 2011, Nature.

[13]  阿部 弥生.  Forkhead box transcription factor, forkhead box A1, shows negative association with lymph node status in endometrial cancer, and represses cell proliferation and migration of endometrial cancer cells , 2012 .

[14]  V. Theodorou,et al.  Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer , 2011, The EMBO journal.

[15]  Wing-Kin Sung,et al.  Cellular reprogramming by the conjoint action of ERα, FOXA1, and GATA3 to a ligand-inducible growth state , 2011, Molecular systems biology.

[16]  I. Mylonas.  Prognostic significance and clinical importance of estrogen receptor α and β in human endometrioid adenocarcinomas , 2010 .

[17]  W. E. Hoogendoorn,et al.  Genomic profile of endometrial tumors depends on morphological subtype, not on tamoxifen exposure , 2010, Genes, chromosomes & cancer.

[18]  Clifford A. Meyer,et al.  Nucleosome Dynamics Define Transcriptional Enhancers , 2010, Nature Genetics.

[19]  S. Badve,et al.  Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores , 2010, Modern Pathology.

[20]  I. Mylonas.  Prognostic significance and clinical importance of estrogen receptor alpha and beta in human endometrioid adenocarcinomas. , 2010, Oncology reports.

[21]  Michael D. Wilson,et al.  ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. , 2009, Methods.

[22]  M. Dillon,et al.  Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence , 2009, Clinical Cancer Research.

[23]  Simak Ali,et al.  Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen , 2008, Nature.

[24]  Clifford A. Meyer,et al.  Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.

[25]  J. Reis-Filho,et al.  Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis , 2007, Journal of Clinical Pathology.

[26]  H. Sommer,et al.  Prognostic significance of oestrogen receptor alpha (ERα) and beta (ERβ), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas , 2007 .

[27]  W. E. Hoogendoorn,et al.  Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer , 2007, Breast Cancer Research and Treatment.

[28]  Charles M Perou,et al.  FOXA1 Expression in Breast Cancer—Correlation with Luminal Subtype A and Survival , 2007, Clinical Cancer Research.

[29]  Carl W. Miller,et al.  FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer , 2006, International journal of cancer.

[30]  H. Sommer,et al.  Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. , 2007, European journal of cancer.

[31]  Jun Song,et al.  CEAS: cis-regulatory element annotation system , 2006, Nucleic Acids Res..

[32]  Luyang Sun,et al.  Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis , 2005, Nature.

[33]  Céline Lefebvre,et al.  From the Cover: Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[35]  A. Swerdlow,et al.  Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. , 2005, Journal of the National Cancer Institute.

[36]  Paul T. Groth,et al.  The ENCODE (ENCyclopedia Of DNA Elements) Project , 2004, Science.

[37]  A. Floore,et al.  Tamoxifen resistance by a conformational arrest of the estrogen receptor alpha after PKA activation in breast cancer. , 2004, Cancer cell.

[38]  J. Fraumeni,et al.  Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. , 2004, Journal of the National Cancer Institute.

[39]  Myles Brown,et al.  Molecular Determinants for the Tissue Specificity of SERMs , 2002, Science.

[40]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[41]  H. Hollema,et al.  Risk and prognosis of endometrial cancer after tamoxifen for breast cancer , 2000, The Lancet.

[42]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[43]  J. Cerhan,et al.  Tamoxifen therapy for breast cancer and endometrial cancer risk. , 1999, Journal of the National Cancer Institute.

[44]  David A. Agard,et al.  The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen , 1998, Cell.

[45]  J. Willem,et al.  Risk of endometrial cancer after tamoxifen treatment of breast cancer , 1994, The Lancet.

[46]  A. Pfleiderer,et al.  Estrogen and progesterone receptors in endometrial cancer and their prognostic relevance , 1991, Gynecologic oncology.